CYP19A1 and breast carcinoma: Several studies that collected data on the evolution of cognitive function in chemotherapy-naïve breast cancer patients treated with aromatase inhibitor and a control arm show a disparity of results in terms of the impact on cognitive function [[52], [53], [54], [55], [56], [57]].